NextCure, Inc. (NXTC) stock
NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.40+0.17 (+2.73%)
Close on Nov 13, 2026Market cap $29.30MP/E –Yield 0.00%
NextCure cash
Cash and short-term investments held at the end of each period.
NextCure's cash was $15.26M at Jun 30, 2026. For fiscal 2025 it was $25.98M, down 6.3% from the year before. The highest annual figure on record is $339.64M in fiscal 2019.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.98M | -6.3% |
| FY2024 | Dec 31, 2024 | $27.73M | +111.9% |
| FY2023 | Dec 31, 2023 | $13.08M | -50.9% |
| FY2022 | Dec 31, 2022 | $26.63M | +115.9% |
| FY2021 | Dec 31, 2021 | $12.34M | -95.7% |
| FY2020 | Dec 31, 2020 | $286.96M | -15.5% |
| FY2019 | Dec 31, 2019 | $339.64M | +150.4% |
| FY2018 | Dec 31, 2018 | $135.63M | +1360.5% |
| FY2017 | Dec 31, 2017 | $9.29M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $15.26M | +211.9% |
| Q1 FY2026 | Mar 31, 2026 | $15.17M | -30.5% |
| Q4 FY2025 | Dec 31, 2025 | $25.98M | -6.3% |
| Q3 FY2025 | Sep 30, 2025 | $7.32M | -73.6% |
| Q2 FY2025 | Jun 30, 2025 | $4.89M | -76.5% |
| Q1 FY2025 | Mar 31, 2025 | $21.83M | +18.9% |
| Q4 FY2024 | Dec 31, 2024 | $27.73M | +111.9% |
| Q3 FY2024 | Sep 30, 2024 | $27.70M | +41.9% |
| Q2 FY2024 | Jun 30, 2024 | $20.85M | -5.3% |
| Q1 FY2024 | Mar 31, 2024 | $18.36M | -38.8% |
| Q4 FY2023 | Dec 31, 2023 | $13.08M | -50.9% |
| Q3 FY2023 | Sep 30, 2023 | $19.52M | -37.2% |
| Q2 FY2023 | Jun 30, 2023 | $22.02M | -21.9% |
| Q1 FY2023 | Mar 31, 2023 | $29.97M | +180.4% |
| Q4 FY2022 | Dec 31, 2022 | $26.63M | +115.9% |
| Q3 FY2022 | Sep 30, 2022 | $31.09M | -15.3% |
| Q2 FY2022 | Jun 30, 2022 | $28.20M | -88.8% |
| Q1 FY2022 | Mar 31, 2022 | $10.69M | -96.1% |
| Q4 FY2021 | Dec 31, 2021 | $12.34M | -95.7% |
| Q3 FY2021 | Sep 30, 2021 | $36.70M | -87.6% |
| Q2 FY2021 | Jun 30, 2021 | $252.20M | -19.6% |
| Q1 FY2021 | Mar 31, 2021 | $271.33M | -17.0% |
| Q4 FY2020 | Dec 31, 2020 | $286.96M | -15.5% |
| Q3 FY2020 | Sep 30, 2020 | $295.13M | +56.1% |
| Q2 FY2020 | Jun 30, 2020 | $313.68M | +58.6% |
| Q1 FY2020 | Mar 31, 2020 | $326.86M | +150.3% |
| Q4 FY2019 | Dec 31, 2019 | $339.64M | +150.4% |
| Q3 FY2019 | Sep 30, 2019 | $189.12M | +677.2% |
| Q2 FY2019 | Jun 30, 2019 | $197.73M | +570.9% |
| Q1 FY2019 | Mar 31, 2019 | $130.59M | +3232.2% |
| Q4 FY2018 | Dec 31, 2018 | $135.63M | +1360.5% |
| Q3 FY2018 | Sep 30, 2018 | $24.34M | – |
| Q2 FY2018 | Jun 30, 2018 | $29.47M | – |
| Q1 FY2018 | Mar 31, 2018 | $3.92M | – |
| Q4 FY2017 | Dec 31, 2017 | $9.29M | – |
See a number that looks wrong?